Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2017 May;15(5):563-573.
doi: 10.6004/jnccn.2017.0059.

NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017

Al B Benson 3rd  1 , Michael I D'Angelica  2 , Daniel E Abbott  3 , Thomas A Abrams  4 , Steven R Alberts  5 , Daniel Anaya Saenz  6 , Chandrakanth Are  7 , Daniel B Brown  8 , Daniel T Chang  9 , Anne M Covey  2 , William Hawkins  10 , Renuka Iyer  11 , Rojymon Jacob  12 , Andrea Karachristos  13 , R Kate Kelley  14 , Robin Kim  15 , Manisha Palta  16 , James O Park  17 , Vaibhav Sahai  18 , Tracey Schefter  19 , Carl Schmidt  20 , Jason K Sicklick  21 , Gagandeep Singh  22 , Davendra Sohal  23 , Stacey Stein  24 , G Gary Tian  25 , Jean-Nicolas Vauthey  26 , Alan P Venook  14 , Andrew X Zhu  27 , Karin G Hoffmann  28 , Susan Darlow  28
Affiliations
Practice Guideline

NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017

Al B Benson 3rd et al. J Natl Compr Canc Netw. 2017 May.

Abstract

The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding locoregional therapy for treatment of patients with hepatocellular carcinoma.

PubMed Disclaimer

Similar articles

  • Guidelines Insights: Hepatobiliary Cancers, Version 2.2019.
    Benson AB, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Anaya DA, Anders R, Are C, Brown D, Chang DT, Cloyd J, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Hammond LJ, Darlow SD. Benson AB, et al. J Natl Compr Canc Netw. 2019 Apr 1;17(4):302-310. doi: 10.6004/jnccn.2019.0019. J Natl Compr Canc Netw. 2019. PMID: 30959462
  • NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022.
    Caudell JJ, Gillison ML, Maghami E, Spencer S, Pfister DG, Adkins D, Birkeland AC, Brizel DM, Busse PM, Cmelak AJ, Colevas AD, Eisele DW, Galloway T, Geiger JL, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Mell LK, Mittal BB, Pinto HA, Rocco JW, Rodriguez CP, Savvides PS, Schwartz D, Shah JP, Sher D, St John M, Weber RS, Weinstein G, Worden F, Yang Bruce J, Yom SS, Zhen W, Burns JL, Darlow SD. Caudell JJ, et al. J Natl Compr Canc Netw. 2022 Mar;20(3):224-234. doi: 10.6004/jnccn.2022.0016. J Natl Compr Canc Netw. 2022. PMID: 35276673
  • NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025.
    Colevas AD, Cmelak AJ, Pfister DG, Spencer S, Adkins D, Birkeland AC, Brizel DM, Busse PM, Caudell JJ, Durm G, Fakhry C, Galloway T, Geiger JL, Gillison ML, Glastonbury C, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Juloori A, Kase M, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Price K, Rocco JW, Rodriguez CP, Schwartz D, Shah JP, Sher D, John MS, Wang H, Weinstein G, Worden F, Bruce JY, Yom SS, Zhen W, Montgomery S, Darlow SD. Colevas AD, et al. J Natl Compr Canc Netw. 2025 Feb;23(2):2-11. doi: 10.6004/jnccn.2025.0007. J Natl Compr Canc Netw. 2025. PMID: 39938471
  • Cancers of the large bowel and hepatobiliary system.
    Treat J, Ahlgren JD, Woolley PV. Treat J, et al. Cancer Chemother Biol Response Modif. 1987;9:264-70. Cancer Chemother Biol Response Modif. 1987. PMID: 2856336 Review. No abstract available.
  • Cancers of the large bowel and hepatobiliary tract.
    Treat J, Woolley PV 3rd. Treat J, et al. Cancer Chemother Biol Response Modif. 1992;13:477-92. Cancer Chemother Biol Response Modif. 1992. PMID: 1327046 Review. No abstract available.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ryerson AB, Eheman CR, Altekruse SF, et al. Annual Report to the Nation on the Status of Cancer, 1975–2012 featuring the increasing incidence of liver cancer. Cancer. 2016;122:1312–1337. - PMC - PubMed
    1. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35–50. - PubMed
    1. Blonski W, Kotlyar DS, Forde KA. Non-viral causes of hepatocellular carcinoma. World J Gastroenterol. 2010;16:3603–3615. - PMC - PubMed
    1. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–923. - PubMed
    1. Takamatsu S, Noguchi N, Kudoh A, et al. Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma. Hepatogastroenterology. 2008;55:609–614. - PubMed

Publication types